哈三联首亏超3.15亿：集采寒流+减值拖累下“翻身仗”要怎么打？丨看财报

Core Viewpoint - Harbin Sanlian Pharmaceutical (002900.SZ) has announced its first annual loss since its A-share listing in 2017, with a projected revenue of 790 million yuan for 2025, a decrease of 30% year-on-year, and a net loss estimated between 315 million to 375 million yuan [2][4]. Revenue and Profitability - The company's revenue is expected to drop by 343 million yuan compared to the previous year, primarily due to a significant decline in sales prices and rigid costs [2][4]. - The basic earnings per share are projected to be between -1.19 and -1 yuan [2][4]. - The net profit attributable to shareholders is forecasted to be -375 million yuan, marking a 739.11% decline year-on-year [4]. Price Pressure and Market Competition - A major factor in the company's poor performance is the decline in sales prices, particularly due to the implementation of centralized drug procurement policies, which have severely impacted the prices of core products [3][4]. - The product "Injection of Yanhuning" is facing an average price drop of 86% due to competitive pressures from 31 companies participating in the procurement [5][6]. - The "Ondansetron Hydrochloride Injection" has seen a price reduction of 56.85% after entering the procurement process, leading to a 37.91% decline in revenue despite increased sales volume [8]. Asset Impairment and Expenses - The company has faced significant asset impairments, with a total of 59.49 million yuan in impairment provisions impacting net profit by over 55 million yuan [11][12]. - Inventory write-downs, particularly for "Injection of Yanhuning," have resulted in a reduction of over 87% in recoverable amounts, contributing to the overall financial strain [11][12]. - High fixed expenses have not decreased in line with revenue, leading to increased expense ratios [13]. Strategic Moves and Future Outlook - In response to the challenges, the company is attempting to pivot towards a health-oriented business model, including the establishment of a new division focused on synthetic biology and the launch of new beauty products [14][18]. - However, the beauty industry is highly competitive, and the synthetic biology sector requires significant investment and long development cycles, posing additional challenges for the company [18].